Xeris Biopharma Holdings (XERS) Operating Expenses (2020 - 2026)

Xeris Biopharma Holdings' Operating Expenses history runs 7 years deep, the most recent figure standing at $75.2 million for Q1 2026.

• Quarterly Operating Expenses rose 18.99% year-over-year to $75.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $279.0 million (up 13.84% YoY) and the FY2025 annual result came in at $266.9 million, up 12.77% from the prior year.
• Operating Expenses was $75.2 million for Q1 2026 at Xeris Biopharma Holdings, up from $69.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $75.2 million in Q1 2026 and bottomed at $44.2 million in Q2 2022.
• A 5-year average of $57.6 million and a median of $54.9 million in 2024 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 105.12% in 2022, while the deepest fall reached 30.68% in 2022.
• Xeris Biopharma Holdings' Operating Expenses stood at $48.3 million in 2022, then climbed by 12.25% to $54.2 million in 2023, then gained by 7.72% to $58.4 million in 2024, then climbed by 18.17% to $69.0 million in 2025, then advanced by 8.95% to $75.2 million in 2026.
• Business Quant data shows XERS's Operating Expenses at $75.2 million in Q1 2026, $69.0 million in Q4 2025, and $67.6 million in Q3 2025.